Roche CEO: Direct Sales Could Halve US Drug Prices

Roche CEO Thomas Schinecker has thrown down the gauntlet, declaring it "very easy" to slash US drug prices by a staggering 50%—if the system allows them to bypass the bloat. In a bold confrontation with the status quo, the head of the Basel-based pharmaceutical titan is proposing a radical shift: cutting out the industry's complex web of intermediaries to sell medicines directly to patients. This is not merely a suggestion; it is a calculated maneuver as Roche engages in high-stakes talks with the US government.

The proposal comes at a critical juncture. With the US administration demanding lower healthcare costs, Schinecker asserts that the solution lies not in punishing innovation, but in dismantling the supply chain inefficiencies that plague the American market. "We go direct," Schinecker stated unequivocally, positioning the Swiss giant as a willing partner in price reform rather than an adversary. This direct-to-patient model could revolutionize how Americans access Swiss-engineered life-saving treatments, potentially dismantling a pricing structure that has long baffled economists and burdened patients. By offering a clear path to halving costs, Roche is effectively putting the ball back in Washington's court.

The true villain in the high drug price saga, according to Roche, is the shadowy network of pharmacy benefit managers (PBMs). Schinecker revealed a startling reality: half of all earnings in the supply chain are siphoned off by these intermediaries. These entities, which control the formularies deciding which drugs receive insurance reimbursement, are taking a massive cut while taking "zero risk" on the complex, capital-intensive process of innovation.

While Swiss pharma companies pour billions into R&D to cure cancer and rare diseases, the US system allows middlemen to inflate costs significantly before the drug ever reaches the patient. This structural flaw creates a parasitic dynamic where value is extracted without contribution to medical advancement. The industry has long blamed this convoluted reimbursement architecture for the discrepancy in pricing. By highlighting this imbalance, Roche is exposing the mechanics of a broken system. The company argues that if the US is serious about affordability, it must confront the gatekeepers who profit from the complexity, rather than solely targeting the manufacturers who engineer the cures.

The specter of President Donald Trump's trade policies looms large over the pharmaceutical sector, with threats of levies reaching a punishing 200%. Trump has already signed an executive order proposing a "Most Favoured Nation" policy, demanding that pharmaceutical giants grant the US price parity with other wealthy nations. This poses a severe threat to the industry's most lucrative market, especially given that US drug prices currently stand at 2.3 times the average of 32 other OECD countries.

However, Roche is not standing still in the face of these headwinds. The company has proactively moved inventories and expanded manufacturing within US borders to shield itself from potential trade shocks. Schinecker emphasizes that pricing reform, not tariffs, is the key variable. The "Most Favoured Nation" clause would force a dramatic recalibration of global pricing strategies. Yet, by offering a voluntary 50% price cut through direct sales, Roche is attempting to sidestep the blunt instrument of tariffs with a surgical solution that addresses the administration's core demand: cheaper drugs for American voters.

Despite the geopolitical turbulence, Roche remains a financial fortress. The company reported a robust first half, with sales climbing 7% to CHF 30.9 billion ($39 billion), outpacing consensus forecasts. Core diluted earnings per share surged to CHF 11.1 million, proving that the Swiss giant can deliver growth even while navigating a hostile regulatory environment. This financial resilience underpins their bold strategic moves.

Looking ahead, Roche is doubling down on its commitment to the American market with a colossal $50 billion investment plan for manufacturing and R&D. "We hope that the US government then also sees... that the companies are intending to produce the medicines that are needed in the US, for the US," Schinecker remarked. This massive capital injection serves a dual purpose: it drives innovation while acting as a political shield against protectionist policies. As Roche maintains its full-year guidance for 2025, the message to investors and politicians alike is clear: Swiss pharma is not retreating; it is entrenching itself deeper into the fabric of American healthcare, ready to weather the storm and rewrite the rules of engagement.